Test shorter rifapentine-based treatment for drug-sensitive TB
Part of Infections, Lungs & breathing clinical trials.
This trial studies whether a rifapentine-based TB regimen can work just as well while shortening treatment time. It’s for people with rifampicin-sensitive, smear-positive lung tuberculosis.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 18 to 60, and your weight is 40 to 80 kg
- You have smear-positive pulmonary (lung) tuberculosis and it is sensitive to rifampicin
- You can sign informed consent (or a parent/guardian consent with participant assent for minors)
- If you can become pregnant and you’re not past menopause, you agree to use effective birth control during treatment
- You do NOT have TB outside the lungs, or large/widespread disease (less than 50% involved and no cavity bigger than 4 cm)
- You must not have known drug-resistant TB to key TB medicines, or serious blood/liver/kidney problems, and you can’t be pregnant or breast-feeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a shorter treatment for a type of TB that is resistant to rifampicin (a common TB medicine) but still sensitive to isoniazid. It aims to see if this shorter regimen is as effective as the current longer one, potentially making treatment less burdensome for patients.
This trial tests whether higher or standard doses of the antibiotic rifampicin work better for treating pulmonary tuberculosis (a lung infection). You may benefit if you are starting TB treatment and have not had a bad reaction to rifampicin before.
This trial tests whether a higher dose of the antibiotic rifampicin can shorten tuberculosis treatment from 6 months to 4 months. If you have drug-sensitive TB, this could mean fewer months of medication and fewer side effects.
This trial tests a shorter treatment for children with tuberculosis (TB) that is not drug-resistant. It aims to find out if a shorter regimen works as well as the standard longer one, making treatment easier for children and their families.
This trial tests a personalized treatment approach for people with rifampicin-resistant TB that is still sensitive to fluoroquinolones. It aims to find the best combination of medicines based on your specific TB profile.
This trial tests whether a shorter treatment using the drug rifampicin is as good as the usual longer treatment for people with less severe tuberculosis (TB). If you join, you'd get a shorter course of pills, which might be more convenient and have fewer side effects.
Hear when a new Tuberculosis, Pulmonary trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.